Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jul;78(2):225–232. doi: 10.1038/bjc.1998.469

Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin's lymphomas and is moderately increased by CD40 ligation.

L Xerri 1, R Bouabdallah 1, E Devilard 1, J Hassoun 1, A M Stoppa 1, F Birg 1
PMCID: PMC2062900  PMID: 9683298

Abstract

The Fas receptor (APO-1/CD95) is capable of inducing apoptosis of lymphoid cells and is expressed in some non-Hodgkin's lymphomas (NHLs). Fas expression is up-regulated at the surface of normal B cells upon triggering of the CD40 receptor. In this report, we investigated the sensitivity of NHLs to Fas-mediated apoptosis induced by anti-Fas monoclonal antibodies (MAbs) and its possible modulation by CD40 ligation in 18 NHL biopsy samples of various histological subtypes. Flow cytometric analysis showed that the fraction of Fas-expressing lymphoma cells was highly variable from sample to sample (from 1% to 93%, mean value 46%). The frequency of apoptotic cells was not significantly increased upon treatment with an anti-Fas MAb compared with control MAb in the 18 NHL cases analysed. The sensitivity of lymphoma cells to Fas-mediated apoptosis was correlated neither with the histological subtypes nor with the level of Fas expression. Activation of neoplastic B cells by CD40 ligation resulted in significant increases in Fas expression and Fas-induced apoptosis among the five B-NHL cases tested. The overall increase in apoptotic rates was moderate and remained lower in tumour samples than in control CD40-activated normal tonsil B cells. Altogether, our results indicate that the sensitivity to Fas-induced apoptosis is null or weak in NHL cells, irrespective of their histological subtype, and that it can be increased to a moderate and variable degree by CD40 ligation on neoplastic B cells. This may be an impediment to the development of Fas-based therapies for NHLs.

Full text

PDF
229

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armitage R. J. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol. 1994 Jun;6(3):407–413. doi: 10.1016/0952-7915(94)90119-8. [DOI] [PubMed] [Google Scholar]
  2. Bakhshi A., Jensen J. P., Goldman P., Wright J. J., McBride O. W., Epstein A. L., Korsmeyer S. J. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell. 1985 Jul;41(3):899–906. doi: 10.1016/s0092-8674(85)80070-2. [DOI] [PubMed] [Google Scholar]
  3. Banchereau J., Bazan F., Blanchard D., Brière F., Galizzi J. P., van Kooten C., Liu Y. J., Rousset F., Saeland S. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881–922. doi: 10.1146/annurev.iy.12.040194.004313. [DOI] [PubMed] [Google Scholar]
  4. Cascino I., Papoff G., De Maria R., Testi R., Ruberti G. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol. 1996 Jan 1;156(1):13–17. [PubMed] [Google Scholar]
  5. Casciola-Rosen L., Nicholson D. W., Chong T., Rowan K. R., Thornberry N. A., Miller D. K., Rosen A. Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death. J Exp Med. 1996 May 1;183(5):1957–1964. doi: 10.1084/jem.183.5.1957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Castigli E., Young F., Carossino A. M., Alt F. W., Geha R. S. CD40 expression and function in murine B cell ontogeny. Int Immunol. 1996 Mar;8(3):405–411. doi: 10.1093/intimm/8.3.405. [DOI] [PubMed] [Google Scholar]
  7. Choe J., Kim H. S., Zhang X., Armitage R. J., Choi Y. S. Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells. Anti-Ig down-regulates Fas expression of CD40 ligand-stimulated germinal center B cells and inhibits Fas-mediated apoptosis. J Immunol. 1996 Aug 1;157(3):1006–1016. [PubMed] [Google Scholar]
  8. Coney L. R., Daniel P. T., Sanborn D., Dhein J., Debatin K. M., Krammer P. H., Zurawski V. R., Jr Apoptotic cell death induced by a mouse-human anti-APO-1 chimeric antibody leads to tumor regression. Int J Cancer. 1994 Aug 15;58(4):562–567. doi: 10.1002/ijc.2910580419. [DOI] [PubMed] [Google Scholar]
  9. Debatin K. M., Goldman C. K., Waldmann T. A., Krammer P. H. APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. Blood. 1993 Jun 1;81(11):2972–2977. [PubMed] [Google Scholar]
  10. Debatin K. M., Goldmann C. K., Bamford R., Waldmann T. A., Krammer P. H. Monoclonal-antibody-mediated apoptosis in adult T-cell leukaemia. Lancet. 1990 Mar 3;335(8688):497–500. doi: 10.1016/0140-6736(90)90735-n. [DOI] [PubMed] [Google Scholar]
  11. Durandy A., Le Deist F., Emile J. F., Debatin K., Fischer A. Sensitivity of Epstein-Barr virus-induced B cell tumor to apoptosis mediated by anti-CD95/Apo-1/fas antibody. Eur J Immunol. 1997 Feb;27(2):538–543. doi: 10.1002/eji.1830270227. [DOI] [PubMed] [Google Scholar]
  12. Friesen C., Herr I., Krammer P. H., Debatin K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996 May;2(5):574–577. doi: 10.1038/nm0596-574. [DOI] [PubMed] [Google Scholar]
  13. Garrone P., Neidhardt E. M., Garcia E., Galibert L., van Kooten C., Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med. 1995 Nov 1;182(5):1265–1273. doi: 10.1084/jem.182.5.1265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gauthier E. R., Piché L., Lemieux G., Lemieux R. Role of bcl-X(L) in the control of apoptosis in murine myeloma cells. Cancer Res. 1996 Mar 15;56(6):1451–1456. [PubMed] [Google Scholar]
  15. Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K., Cleary M. L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K. C. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994 Sep 1;84(5):1361–1392. [PubMed] [Google Scholar]
  16. Henkart P. A. ICE family proteases: mediators of all apoptotic cell death? Immunity. 1996 Mar;4(3):195–201. doi: 10.1016/s1074-7613(00)80428-8. [DOI] [PubMed] [Google Scholar]
  17. Itoh N., Tsujimoto Y., Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol. 1993 Jul 15;151(2):621–627. [PubMed] [Google Scholar]
  18. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991 Jul 26;66(2):233–243. doi: 10.1016/0092-8674(91)90614-5. [DOI] [PubMed] [Google Scholar]
  19. Jain R., Roncella S., Hashimoto S., Carbone A., Francia di Celle P., Foa R., Ferrarini M., Chiorazzi N. A potential role for antigen selection in the clonal evolution of Burkitt's lymphoma. J Immunol. 1994 Jul 1;153(1):45–52. [PubMed] [Google Scholar]
  20. Korsmeyer S. J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992 Aug 15;80(4):879–886. [PubMed] [Google Scholar]
  21. Krajewski S., Gascoyne R. D., Zapata J. M., Krajewska M., Kitada S., Chhanabhai M., Horsman D., Berean K., Piro L. D., Fugier-Vivier I. Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin's lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes. Blood. 1997 May 15;89(10):3817–3825. [PubMed] [Google Scholar]
  22. Landowski T. H., Gleason-Guzman M. C., Dalton W. S. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood. 1997 Mar 15;89(6):1854–1861. [PubMed] [Google Scholar]
  23. Lynch D. H., Watson M. L., Alderson M. R., Baum P. R., Miller R. E., Tough T., Gibson M., Davis-Smith T., Smith C. A., Hunter K. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity. 1994 May;1(2):131–136. doi: 10.1016/1074-7613(94)90106-6. [DOI] [PubMed] [Google Scholar]
  24. Möller P., Henne C., Leithäuser F., Eichelmann A., Schmidt A., Brüderlein S., Dhein J., Krammer P. H. Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas. Blood. 1993 Apr 15;81(8):2067–2075. [PubMed] [Google Scholar]
  25. Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C., Li-Weber M., Richards S., Dhein J., Trauth B. C. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem. 1992 May 25;267(15):10709–10715. [PubMed] [Google Scholar]
  26. Peng S. L., Robert M. E., Hayday A. C., Craft J. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J Exp Med. 1996 Sep 1;184(3):1149–1154. doi: 10.1084/jem.184.3.1149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Plumas J., Jacob M. C., Chaperot L., Molens J. P., Sotto J. J., Bensa J. C. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood. 1998 Apr 15;91(8):2875–2885. [PubMed] [Google Scholar]
  28. Rensing-Ehl A., Frei K., Flury R., Matiba B., Mariani S. M., Weller M., Aebischer P., Krammer P. H., Fontana A. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol. 1995 Aug;25(8):2253–2258. doi: 10.1002/eji.1830250821. [DOI] [PubMed] [Google Scholar]
  29. Schattner E. J., Elkon K. B., Yoo D. H., Tumang J., Krammer P. H., Crow M. K., Friedman S. M. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med. 1995 Nov 1;182(5):1557–1565. doi: 10.1084/jem.182.5.1557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Schattner E. J., Mascarenhas J., Bishop J., Yoo D. H., Chadburn A., Crow M. K., Friedman S. M. CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lymphoma B cells. Blood. 1996 Aug 15;88(4):1375–1382. [PubMed] [Google Scholar]
  31. Wang D., Freeman G. J., Levine H., Ritz J., Robertson M. J. Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol. 1997 May;97(2):409–417. doi: 10.1046/j.1365-2141.1997.422688.x. [DOI] [PubMed] [Google Scholar]
  32. Watanabe-Fukunaga R., Brannan C. I., Copeland N. G., Jenkins N. A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992 Mar 26;356(6367):314–317. doi: 10.1038/356314a0. [DOI] [PubMed] [Google Scholar]
  33. Westendorf J. J., Lammert J. M., Jelinek D. F. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood. 1995 Jun 15;85(12):3566–3576. [PubMed] [Google Scholar]
  34. Xerri L., Devilard E., Ayello C., Brousset P., Reed J. C., Emile J. F., Hassoun J., Parmentier S., Birg F. Cysteine protease CPP32, but not Ich1-L, is expressed in germinal center B cells and their neoplastic counterparts. Hum Pathol. 1997 Aug;28(8):912–921. doi: 10.1016/s0046-8177(97)90006-x. [DOI] [PubMed] [Google Scholar]
  35. Xerri L., Parc P., Brousset P., Schlaifer D., Hassoun J., Reed J. C., Krajewski S., Birnbaum D. Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas. Br J Haematol. 1996 Mar;92(4):900–906. doi: 10.1046/j.1365-2141.1996.423958.x. [DOI] [PubMed] [Google Scholar]
  36. Zhang C., Ao Z., Seth A., Schlossman S. F. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J Immunol. 1996 Nov 1;157(9):3980–3987. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES